Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 849 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Prospective Blood Draw Clear all

Conditions: Arthritis
Interventions: Vitagel; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anal Fistula
Interventions: RD2 Ver.02, Saline; Device · Other
Lead sponsor: RedDress Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • Weston, Florida • Chicago, Illinois + 6 more

Conditions: Aortic Valve Stenosis
Interventions: Echocardiography, Computed tomography, Magnetic resonance imaging, Blood biomarkers, Stress echocardiography; Other
Lead sponsor: Laval University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2024
U.S. locations: 2
States / cities: Rochester, Minnesota • Pittsburgh, Pennsylvania

Conditions: Chronic Lymphocytic Leukemia (CLL)
Interventions: Obinutuzumab, Venetoclax, Fludarabine, Cyclophosphamide, Rituximab, Bendamustine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Aurora, Colorado • Bethesda, Maryland • Knoxville, Tennessee + 1 more

Conditions: Evidence of Liver Transplantation, Hyperglycemia, Rejection
Interventions: Insulin; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: In Utero Procedure Affecting Fetus or Newborn
Interventions: KARL STORZ fetoscope arm; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Benign Prostatic Hyperplasia
Interventions: Prostate Arterial Embolization; Device
Lead sponsor: Antonios Likourezos; Other
Eligibility: 35 Years to 99 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Cancer, Immune-related Adverse Event
Interventions: Medical chart review; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Uveitis
Interventions: infliximab; Drug
Lead sponsor: Egla C. Rabinovich; Other
Eligibility: 4 Years to 18 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neoplasms, Cancer
Interventions: Not listed
Lead sponsor: GRAIL, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 99,481 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 35
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Elk Grove, California + 31 more

Conditions: Osteoarthritis, Intraoperative Bleeding
Interventions: Evicel Fibrin Spray; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Oak Park, Illinois

Conditions: Diabetes
Interventions: Prospective Blood Draw; Other
Lead sponsor: Fujirebio Diagnostics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Gulf Shores, Alabama

Conditions: Choledocholithiasis, Cholangiocarcinoma, Benign Stricture of Common Bile Duct
Interventions: Blood culture ( aerobic and anaerobic); Other
Lead sponsor: Texas Tech University Health Sciences Center, El Paso; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Multiple Myeloma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Interventions: Plerixafor, Gcsf; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: IUGR, Pregnancy
Interventions: Ultrasound, MRI, Blood collection, Neurological Function Assessment, Placental Analysis, Measurement of body fat, Pediatric heart ultrasound; Radiation · Procedure · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Prostate Cancer
Interventions: Collection of plasma samples; Other
Lead sponsor: DiaCarta, Inc.; Industry
Eligibility: 30 Years to 85 Years · Male only
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Gainesville, Florida • Jacksonville, Florida • New York, New York + 2 more

Conditions: Prehypertension, Hypertension, Stage I
Interventions: B244, Vehicle; Biological
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tustin, California + 7 more

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: alemtuzumab, busulfan, cyclophosphamide, methotrexate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Graft vs Host Disease, Cutaneous Sclerosis, Bronchiolitis Obliterans
Interventions: Not listed
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 911 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 14
States / cities: Scottsdale, Arizona • Stanford, California • Tampa, Florida + 11 more

Conditions: Hematuria - Cause Not Known
Interventions: Cxbladder Triage Plus; Diagnostic Test
Lead sponsor: Pacific Edge Limited; Industry
Eligibility: 18 Years to 88 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 20
States / cities: Homewood, Alabama • Mobile, Alabama • Fresno, California + 15 more

Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasm
Interventions: Screening Blood Tests, Endoscopic Ultrasound, Magnetic Resonance Imaging, Magnetic Resonance Cholangiopancreatography; Other · Diagnostic Test · Combination Product
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2041
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Bacteremia
Interventions: Not listed
Lead sponsor: MicroPhage, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 764 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 3
States / cities: Tuscon, Arizona • Los Angeles, California • Charleston, South Carolina

Conditions: Kidney Transplant, Liver Transplant
Interventions: Blood Draw; Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 5
States / cities: San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 2 more

Conditions: Septic Shock, Endotoxemia
Interventions: Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge; Device
Lead sponsor: Spectral Diagnostics (US) Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 16 more

Search by objective public record fields.

Prospective Evaluation of Vitagel for Reduction in Blood Loss and Pain Following Unilateral Total Knee Arthroplasty

A Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02 For the Management of Anal Fistulas

Multicenter Prospective Study of Low-Flow Low-Gradient Aortic Stenosis (TOPAS Study)

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Study of Glycemic Control on Liver Transplantation Outcomes

The Use of Karl Storz Curved Fetoscope (11508aak) and Its Straight Version (11506akk) for In-utero Surgery

Analysis of Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Using Embosphere Microspheres

Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy

Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis

The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types

Use of a Novel Fibrin Sealant in Total Knee Arthroplasty

A Prospective Collection of Peripheral Blood and Urine Specimens to Study C-peptide and Insulin in Healthy Individuals

Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD

Mozobil for Autologous Hematopoietic Stem Cell Transplantation

Longitudinal Study of Intra-Uterine Growth Restriction

Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation Toxicity

A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA

A Cohort Study of Operationally Tolerant Allograft Recipients

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study